|apersy|

Value | Market Access | Commercialisation

Tag: AMNOG

  • December 2022 Market Access news recap

    December 2022 Market Access news recap

    The monthy 3 minutes of selected bits of news: 62 seconds on DiPAs – digital care and nursing applications are launching in Germany Microbiome product Rebyota is now approved in the US – we are keenly watching out for access, uptake and reimbursement learnings… AIFA reimbursement committees merge Germany rare disease medicine Brineura to recevie…

  • August & September 2022 Market Access news recap

    August & September 2022 Market Access news recap

    After the summer break, let’s quickly catch-up with selected August and September news from the access and reimbursement sphere….

  • July 2022 Market Access news recap

    July 2022 Market Access news recap

    Three minutes selected reimbursement and pricing news from July, including the latest updates on the reform of German AMNOG early benefit assessment & pricing process.

  • Germany: Changes to innovative drug pricing and AMNOG ahead?

    Germany: Changes to innovative drug pricing and AMNOG ahead?

     The first draft of the GKV finance stabilization act (GKV FinStG) has just been presented and holds tough news for industry. An outline of the key pricing and AMNOG changes proposed:  The schedule  for the further consultations on the law is not yet clear. Industry has already heavily critised the draft, seeing innovation not sufficiently rewarded…